血清低水平丙氨酸氨基转移酶的HBV感染者临床特征分析*

doi:10.3969/j.issn.1672-5069.2022.03.010

摘要/Abstract

摘要： 目的分析总结低水平血清丙氨酸氨基转移酶(ALT)的HBV感染者临床特征,以利于寻找肝功能可能已经异常的线索。方法 2017年1月～2021年3月我院诊治的HBV感染者226例,均接受肝活检,采用Scheuer评分系统和组织学活动指数评价肝组织纤维化分期和炎症活动度分级。将肝组织炎症活动度分级和肝纤维化分期≥G2S2定义为显著肝组织学病变。结果在本组226例HBV感染者中,临床诊断HBV携带者125例,慢性乙型肝炎(CHB)患者101例;CHB患者男性占比、显著肝组织病变、血清AST水平>40 U/L、肝纤维化分期≥F2和肝组织炎症活动度≥G2分别为77.2%、61.4%、49.5%、36.7%和52.5%,显著高于HBV携带者的54.4%、33.6%、5.6%、18.4%和25.6%(P<0.05);在226例HBV感染者中,经肝组织学检查,发现显著肝组织病变104例,非显著肝组织病变122例;显著肝组织病变患者血清HBV DNA水平为(4.6±1.2)lg copies/ml,显著低于非显著组【(5.2±1.4)lg copies/ml,P<0.05】,外周血血小板计数为(163.6±49.2)×10⁹/L,显著低于非显著组【(192.2±54.5)×10⁹/L,P<0.05】,血清ALT水平>40 U/L、AST水平>40 U/L、肝纤维化分期≥F2和肝组织炎症活动度分级≥G2占比分别为60.6%、39.4%、57.7%和81.7%,显著高于非显著组(分别为31.1%、13.1%、0.0%和0.0%,P<0.05)。结论对于血清ALT低水平的HBV感染者应进行临床资料的筛查和甄别,其中一些已经存在肝组织学病变,适时进行肝活检可以帮助早期发现CHB患者而给予必要的处理,以改善预后。

关键词: 乙型肝炎病毒感染者, 慢性乙型肝炎, 丙氨酸氨基转移酶, 肝纤维化, 肝组织炎症活动度

Abstract: Objective The aim of this study was to summarize the clinical clues for early liver biopsies in chronic hepatitis B viral infected individuals with low serum alanine aminotransferase (ALT) levels. Methods 226 chronic hepatitis B viral infected individuals with low serum ALT levels were admitted to our hospital between January 2017 and March 2021,and all underwent liver biopsies. The liver injuries were evaluated by Scheuer scoring system for liver fibrosis staging and by histological activity index for inflammatory activity grading. The significant liver injuries were defined as the liver fibrosis≥S2 and/or the inflammatory activity≥G2. Results Out of the 226 individuals with HBV infection and low serum ALT levels, the clinical diagnosis was chronic HBV carriers in 125 cases, and chronic hepatitis B (CHB) in 101 cases; the percentages of male, significant liver injury, serum AST >40 U/L, liver fibrosis ≥F2 and liver inflammation ≥G2 in patients with CHB were 77.2%, 61.4%, 49.5%, 36.7% and 52.5%, all significantly higher than 54.4%, 33.6%, 5.6%, 18.4% and 25.6% in HBV carriers(P<0.05); out of the 226 individuals in our series, the liver histopathological examination showed significant liver injuries in 104 cases and non-significant liver injuries in 122 cases; serum HBV DNA load in patients with significant liver injury was(4.6±1.2) lg copies/ml, significantly lower than [(5.2±1.4)lg copies/ml, P<0.05], peripheral blood platelet count was (163.6±49.2)×10⁹/L, significantly lower than [(192.2±54.5)×10⁹/L, P<0.05] in individuals without significant liver injury, and the percentages of serum ALT level greater than 40 U/L, serum AST level greater than 40 U/L, liver fibrosis greater than F2 staging and liver inflammation greater than G2 grading were 60.6%, 39.4%, 57.7% and 81.7%, significantly higher than 31.1%, 13.1%, 0.0% and 0.0%, respectively (P<0.05) in individuals without significant liver injury. Conclusion The clinical feature of individuals with chronic hepatitis B viral infection and low serum ALT levels is subtle, and some clues might hint liver injury and warrant further liver biopsy, which could present the liver histopathological grading and staging and help the clinicians to make decisions.

Key words: Hepatitis B virus carriers, Chronic hepatitis B, Alanine aminotransferase, Liver fibrosis, Histological activity index

严兆兰, 祖红梅, 蔡长霞, 魏巍. 血清低水平丙氨酸氨基转移酶的HBV感染者临床特征分析^*[J]. 实用肝脏病杂志, 2022, 25(3): 343-346.

Yan Zhaolan, Zu Hongmei, Cai Changxia, et al. Clinical features of chronic hepatitis B viral infected individuals with low serum alanine aminotransferase levels: clues for early liver biopsies[J]. Journal of Practical Hepatology, 2022, 25(3): 343-346.

参考文献

[1] Gish RG, Given BD, Lai CL, et al. Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities. Antiviral Res, 2015, 121:47-58.
[2] David G, Fogeron ML, Montserret R, et al. Phosphorylation and alternative translation on wheat germ cell-free protein synthesis of the DHBV large envelope protein. Front Mol Biosci, 2019, 6:138.
[3] Butt N, Khan MA, Haleem F. Acute viral hepatitis: Simultaneous infection from hepatitis A, B and E viruses. J Coll Physicians Surg Pak, 2019,29(12):S103-S105.
[4] Fukuda W, Hanyu T, Katayama M, et al. Risk stratification and clinical course of hepatitis B virus reactivation in rheumatoid arthritis patients with resolved infection: final report of a multicenter prospective observational study at Japanese Red Cross Hospital. Arthritis Res Ther, 2019,21(1):255.
[5] Wang K, Lu X, Zhou H, et al. Deep learning Radiomics of shear wave elastography significantly improved diagnostic performance for assessing liver fibrosis in chronic hepatitis B: a prospective multicentrestudy. Gut, 2019, 68(4):729-741.
[6] Sonneveld MJ, Brouwer WP, Hansen BE, et al. Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis. Aliment Pharmacol Ther, 2020, 52(8):1399-1406.
[7] Seto WK, Liu KS, Mak LY, et al. Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation. Gut, 2021, 70(4):775-783.
[8] Velati C, Romanò L, Pati I,et al. Prevalence, incidence and residual risk of transfusion-transmitted hepatitis B virus infection in Italy from 2009 to 2018. Blood Transfus, 2019, 17(6):409-417.
[9] MacLachlan JH, Romero N, Higgins N, etal. Epidemiology of chronic hepatitis B and C in Victoria, Australia: insights and impacts from enhanced surveillance. Aust N Z J Public Health, 2020, 44(1):59-64.
[10] 史艳敏, 储芳, 史策, 等. HBV cccDNA及HBsAg定量对慢性乙型肝炎患儿抗病毒疗效判断的应用价值. 中华肝脏病杂志, 2018, 26(1):63-65.
[11] Liu Y, Jiang M, Xue J, et al. Serum HBV RNA quantification: useful for monitoring natural history of chronic hepatitis B infection. BMC Gastroenterol, 2019, 19(1):53.
[12] Fopa D, Candotti D, Tagny CT, et al. Occult hepatitis B infection among blood donors from Yaoundé, Cameroon. Blood Transfus, 2019,17(6):403-408.
[13] Kumar M, Sarin SK, Hissar S, et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology, 2008, 134(5):1376-1384.
[14] Chen EQ, Huang FJ, He LL, et al. Histological changes in chronic hepatitis B patients with ALT lower than two times upper limits of normal. Dig Dis Sci, 2010, 55(2):432-437.
[15] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2019年版).实用肝脏病杂志,2020,23(1)S9-32.
[16] Lai M, Hyatt BJ, Nasser I, et al. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol, 2007, 47(6):760-767.
[17] Chotiyaputta W, Degertekin B, McKenna BJ, et al. Characteristics of chronic hepatitis B patients who underwent liver biopsies. J Viral Hepat, 2011, 18(11):792-803.
[18] Yang N, Feng J, Zhou T, et al. Relationship between serum quantitative HBsAg and HBV DNA levels in chronic hepatitis B patients. J Med Virol, 2018, 90(7):1240-1245.
[19] 吴泽倩, 谭雷, 刘婷, 等. HBeAg阴性慢性乙型肝炎患者血清HBsAg水平在不同肝组织炎症分级和纤维化分期的变化. 中华肝脏病杂志, 2014, 22(12): 895-899.
[20] 闫一杰, 王晓晓, 曹振环, 等. 48周HBsAg低水平的HBeAg阴性慢性乙型肝炎患者是获得HBsAg清除的优势人群. 中华肝脏病杂志, 2018, 26(11): 813-818.
[21] Cai S, Li Z, Yu T, et al. Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs. Infect Drug Resist, 2018, 11:469-477.
[22] Puoti C. How to manage HBeAg-negative chronic HBV infection with normal alanine aminotransferase levels in clinical practice? Eur J Intern Med, 2013, 24(2):100-103.
[23] Cheng JL, Wang XL, Yang SG, et al. Non-ALT biomarkers for markedly abnormal liver histology among Chinese persistently normal alanine aminotransferase-chronic hepatitis B patients. World J Gastroenterol, 2017, 23(15):2802-2810.
[24] Li MR, Zheng HW, Ma SM, et al. Correlations between serum hepatitis B surface antigen and hepatitis B core antibody titers and liver fibrosis in treatment-naïve CHB patients.J Chin Med Assoc, 2018, 81(12):1052-1059.
[25] Tsuji Y, Namisaki T, Kaji K, et al. Comparison of serum fibrosis biomarkers for diagnosing significant liver fibrosis in patients with chronic hepatitis B. Exp Ther Med, 2020, 20(2):985-995.

血清低水平丙氨酸氨基转移酶的HBV感染者临床特征分析^*

Clinical features of chronic hepatitis B viral infected individuals with low serum alanine aminotransferase levels: clues for early liver biopsies

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	郭悦承, 陆伦根. 肝纤维化临床诊断与治疗研究进展[J]. 实用肝脏病杂志, 2022, 25(3): 305-308.
[2]	韩冰, 涂传涛. NASH患者肝巨噬细胞在肝纤维化形成过程中的作用及其临床转化研究进展^*[J]. 实用肝脏病杂志, 2022, 25(3): 309-313.
[3]	黄俊榕, 吴昌儒, 吴健林. 恩替卡韦联合甘草酸二铵治疗慢性乙型肝炎患者效果研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 327-330.
[4]	邹东花, 秘建威, 李玉苓, 赵森. 阿德福韦酯分别联合恩替卡韦或替诺福韦治疗rtA181V/T单位点突变的慢性乙型肝炎患者疗效初步研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 331-334.
[5]	罗珂, 丁莉, 刘美. 慢性乙型肝炎患者血清miR-21和miR-148b水平变化及其预测肝组织炎症分级和纤维化分期价值探讨^*[J]. 实用肝脏病杂志, 2022, 25(3): 335-338.
[6]	王广丽, 徐欢, 董丹丹, 黄荷. 慢性乙型肝炎患者血清HBV恩替卡韦耐药基因突变模式调查^*[J]. 实用肝脏病杂志, 2022, 25(3): 339-342.
[7]	李春花, 李忠新, 张春雷, 曾学辉, 陈甜甜, 宋林立. 不同肝纤维化程度的慢性乙型肝炎患者血清FGF-21、PDGF-BB和FBRS水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(3): 347-350.
[8]	姜悦萌, 马于琪, 阚春明, 尹华发. 应用核苷(酸)类治疗慢性乙型肝炎患者早期肾功能的变化^*[J]. 实用肝脏病杂志, 2022, 25(3): 351-354.
[9]	周兴, 易怀红, 宋廉. 超声弹性成像声触诊组织成像量化指标评估肝血吸虫病患者肝纤维化价值临床研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 399-402.
[10]	杨艳, 刘婷, 戴琳, 努丽曼姑·麦麦提, 刘环. 声触诊弹性成像检测肝脾硬度诊断慢性乙型肝炎患者肝纤维化效能分析^*[J]. 实用肝脏病杂志, 2022, 25(2): 183-186.
[11]	黄平, 曾霞, 张亚萍, 毛加丽. 肝静脉波形分型联合肝脏超声半定量评分对慢性乙型肝炎患者肝纤维化程度评估价值研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 187-190.
[12]	李振, 宁姗姗, 郭影, 王甜甜, 李莉华, 叶美红, 宋源源. 慢性乙型肝炎患者肝组织LXRα和CYP7A1基因水平变化及其与肝组织炎症和纤维化程度的关系研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 191-194.
[13]	郑淑颖, 郭欢欢, 程长浩, 冯珍珍. 索非布韦联合雷迪帕韦治疗慢性丙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(1): 26-29.
[14]	许政衡, 黄勇, 柯海霞, 李南, 马乙云. 慢性乙型肝炎患者外周血单个核细胞Galectin-3基因水平对聚乙二醇干扰素α治疗应答的影响^*[J]. 实用肝脏病杂志, 2021, 24(6): 811-814.
[15]	王利公, 赵珊, 白凯, 张宁, 张楠. 慢性乙型肝炎患者血清α1酸性糖蛋白、α1-抗胰蛋白酶和触珠蛋白变化及其临床意义探讨[J]. 实用肝脏病杂志, 2021, 24(5): 673-676.